Addressing the Limitations of Current ITP Therapies

EP: 1.Understanding Immune Thrombocytopenia: Pathophysiology, Classification, and Differentiation

EP: 2.Diagnostic and Patient Education Strategies in ITP

EP: 3.Managing Bleeding Risk in Patients with ITP

EP: 4.Living with ITP: Impact of Fatigue and Other Symptoms on Patients’ Quality of Life

EP: 5.Tailoring Care in ITP Through a Health Equity Lens

EP: 6.Looking Ahead in ITP: Addressing Unmet Needs and Embracing Innovation

EP: 7.Key Clinical Signs and Symptoms Used in Diagnosis of Immune Thrombocytopenia

EP: 8.Clinical Decision-Making in ITP: Timing Treatment Initiation and Therapy Goals

EP: 9.Current Treatment Algorithm for Management of Immune Thrombocytopenia

Now Viewing

EP: 10.Addressing the Limitations of Current ITP Therapies

Understanding the limitations of ITP therapy is crucial for both clinicians and patients. A key part of care involves thorough patient education—starting with what ITP is, how it presents, and what warning signs to watch for. Patients are taught to recognize bleeding symptoms and are advised on when treatment may be urgently needed. In some cases, patients are given “back-pocket” steroids to use in emergencies, especially if traveling or away from their treatment center. This proactive planning ensures they have access to treatment should symptoms arise while they’re away.

For patients in the persistent or chronic phase of ITP, treatment preferences often influence therapy choice. Many prefer short-term treatment regimens that do not require ongoing visits to a clinic. Options such as intravenous immunoglobulin (IVIG) or rituximab may offer temporary relief without long-term medication use. However, for those who require ongoing therapy, the goal remains consistent: to maintain a platelet count above 20,000–30,000 without active bleeding, using the lowest effective dose. Some patients may receive subcutaneous treatments like romiplostim, which necessitate frequent clinic visits, but most prefer oral therapies due to convenience and flexibility.

Shared decision-making is emphasized in long-term management. Discussions with patients cover the pros and cons of IV, subcutaneous, and oral therapies. Patients’ lifestyle, proximity to treatment centers, and overall support system are all factored into the treatment plan. In complex cases involving comorbidities—like diabetes or cardiovascular disease—an interdisciplinary approach is essential. For example, high-dose steroids can significantly disrupt blood sugar levels, requiring input from primary care or endocrinology. Ultimately, managing ITP successfully involves personalized care, education, flexibility in treatment planning, and close coordination among healthcare providers to support each patient’s unique needs and clinical circumstances.